One of the biggest violations was a continuing failure to investigate complaints in a timely manner. The report cited a backlog of 1,360 investigations. So far, Novartis estimates losses at $115 million in direct costs related to the shutdown and $85 million in lost sales.
Related Articles on Supply Chain:
The Year to Cut Supply Costs: 5 ASC Supply Chain Trends With Richard Peters of Provista
Study Claims FDA Drug Warnings Often Ineffective
Amerinet Announces New Supplier Agreements With AXIOM, H2O Applied Technologies & Paddock Laboratories
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
